Key Facts
- Drug: MIUDELLA
- Class: Hormone-free intrauterine device
- Action: FDA accepted an sNDA
- Indication: Not disclosed
- Efficacy: No outcomes reported
- Safety: No signals reported
- Status: Under FDA review
- Geography: United States
News|Articles|September 14, 2026
FDA Accepts Extended Duration sNDA for Miudella Hormone-Free IUD
Author(s)Sydney Jennings
Fact checked by: Abigail Brooks, MA
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Advertisement
The FDA has accepted Organon’s supplemental new drug application (sNDA) for MIUDELLA, which the company describes as “a hormone-free intrauterine device.”¹ Acceptance places the application into agency review but does not indicate that the requested change will ultimately be approved.
The clinical implications remain uncertain because the publicly available source did not disclose the supplement’s proposed indication, supporting studies, review deadline, or efficacy and safety results. No attributable comments from company representatives, investigators, or clinicians were available on the source page.¹
An sNDA is used to request FDA approval for a change involving a product with an existing approved new drug application. Depending on the supplement, proposed changes can involve an indication, formulation, dosing regimen, manufacturing process, or labeling. FDA acceptance generally means that the application is sufficiently complete for substantive review; it is not a determination that the evidence meets the standard for approval.²
Organon did not report whether the agency assigned the application standard or priority review, whether an advisory committee meeting is anticipated, or when an action decision is expected. The source also did not identify the composition of MIUDELLA beyond describing the device as hormone-free.¹ Consequently, MIUDELLA should not be assumed to have the same mechanism, duration of use, adverse-event profile, or contraindications as currently available copper-containing intrauterine devices.
Hormone-free intrauterine contraception may be relevant for patients who prefer to avoid exogenous hormones or have clinical considerations affecting use of hormonal methods. In current US practice, intrauterine devices are considered long-acting reversible contraceptive methods. Method selection should reflect contraceptive goals, medical eligibility, expected bleeding effects, procedural considerations, and patient preference.³
For clinicians, the most important unanswered issue is the specific change Organon is asking the FDA to authorize. If the supplement seeks a new indication or longer duration of use, review would ordinarily focus on contraceptive effectiveness over the proposed interval, continuation and discontinuation rates, pregnancy outcomes, and adverse events. If the request concerns labeling or manufacturing, the immediate effect on clinical practice could be narrower.
No trial name, phase, comparator, sample size, demographic profile, or primary end point was reported in the accessible material. Rates of pregnancy, expulsion, perforation, pelvic infection, abnormal bleeding, pain, or treatment discontinuation also were not provided. These omissions prevent an independent assessment of benefit-risk balance or comparison with established intrauterine contraceptive options.
Additional evidence will be needed to determine whether MIUDELLA offers clinically meaningful differences in effectiveness, duration, insertion characteristics, bleeding patterns, or tolerability. Publication of the supporting data and release of FDA review documents would allow clinicians to evaluate study design, population representativeness, missing data, and adverse-event ascertainment.
Until the FDA completes its review, the acceptance should be interpreted as a procedural milestone rather than a recommendation for use. Any eventual clinical role will depend on the precise indication, final labeling, contraindications, duration of effectiveness, and safety findings authorized by the agency.
References
- Organon announces US FDA has accepted for review a supplemental new drug application for MIUDELLA, a hormone-free intrauterine device. BusinessWire. September 14, 2026.
https://www.businesswire.com/news/home/20260914839018/en/Organon-Announces-US-FDA-Has-Accepted-for-Review-a-Supplemental-New-Drug-Application-for-MIUDELLA-a-Hormone-Free-Intrauterine-Device - US Food and Drug Administration. Code of Federal Regulations, Title 21, §314.101: Filing an NDA and receiving an ANDA.
- Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(No. RR-3):1-77.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Why Prostate Cancer Screening Belongs in Primary Care
2
Endocrine Society Calls for Obesity Treatment Goals Beyond Weight Loss
3
Stroke Prevention Starts in Primary Care, Vascular Neurologist Says
4
Probiotic Use Surges as Fiber Intake Stagnates in US Adults, Young Adults
5